Ecnoglutide
GLP-1 (biased agonist) · s.c. · Sciwind
Summary
- Also known as
- XW003
- Mechanism
- GLP-1 (biased agonist)
- Route
- s.c.
- Company
- Sciwind
- Highest development stage
- approved
- Status (as of data cut)
- Approved in China: T2D (January 2026) and weight management (March 2026); SLIMMER published (Lancet Diabetes Endocrinol 2025) verify
- Next milestone
- Global development (Verdiva/Pfizer licence for oral)
Sources for the status
Indications: regulatory and evidence status
| Indication | Code | Status | Evidence |
|---|---|---|---|
| Obesity | 4 approved / in label | NMPA (China), weight management, March 2026 | NMPA approval, Sciwind press release (Mar 2026); EECOH-1 |
| T2D | 4 approved / in label | NMPA (China), January 2026 | NMPA approval, Sciwind press release (Jan 2026) |
| CV outcomes | 0 no data | ||
| CKD | 0 no data | ||
| HFpEF | 0 no data | ||
| MASH | 0 no data | ||
| Sleep apnoea | 2 phase 3 ongoing | Phase 3 ongoing | |
| Knee OA | 2 phase 3 ongoing | Phase 3 ongoing | |
| Alzheimer's | 0 no data |
4 = approved / in a label (FDA, EMA or NMPA), 3 = positive phase 3, 2 = phase 3 ongoing or completed without public results, 1 = phase 2 or signal only, 0 = no data, −1 = negative phase 3/4. L = label, P = PubMed, T = registry.
Trial arms: weight, HbA1c and tolerability
| Trial | Arm | Population | Weeks | n | Weight, efficacy | Weight, treatment-policy | HbA1c, pp | AE discontinuation, % | Any discontinuation, % | Nausea, % | Vomiting, % | SAE, % | SBP, mmHg | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SLIMMER-UP-SWITCH (interim) | 2.4 mg vs semaglutide 2.4 mg: weight -9.5 % | obesity china | 20 | 163 | — | —−12.8 % estimand not specified | — | — | — | — | — | — | — | press release |
| EECOH-1 | 0.6 mg | t2d china | 24 | 211 | — | —−4.5 % vs −2.0 % estimand not specified | −2.0 vs −0.9 | 1.4 vs 1.4 | 4.3 vs 2.8 | 7.2 vs 9.9 | — | 2.9 vs 5.6 | — | press release |
| EECOH-1 (T2D monotherapy) | ecnoglutide 1.2 mg | t2d china | 24 | 71 | — | −4.7 % vs −2.0 % Δ −2.7 pp | −2.4 vs −0.9 | 1.4 vs 1.4 | 5.6 vs 2.8 | 12.7 vs 9.9 | — | 4.2 vs 5.6 | −5.2 vs −2.1 | verified |
| EECOH-2 | 0.6 mg vs dulaglutide 1.5 mg: HbA1c -1.65 | t2d china | 32 | 623 | — | — | −1.9 | 3.0 | — | — | — | — | — | press release |
| EECOH-2 | 1.2 mg vs dulaglutide 1.5 mg: HbA1c -1.65 | t2d china | 32 | 623 | — | — | −1.9 | 4.0 | — | — | — | — | — | press release |
| SLIMMER | 1.2 mg | obesity china | 48 | 664 | — | −9.9 % vs −0.3 % Δ −9.6 pp | — | — | — | — | — | — | — | press release |
| SLIMMER | 1.8 mg | obesity china | 48 | 664 | — | −13.3 % vs −0.3 % Δ −13.0 pp | — | — | — | — | — | — | — | press release |
| SLIMMER | 2.4 mg | obesity china | 48 | 664 | — | −15.4 % vs −0.3 % Δ −15.1 pp | — | — | — | — | — | — | — | press release |
Weight: percent change from baseline, drug vs placebo or comparator, Δ = difference in percentage points. Efficacy estimand = effect while on treatment (hypothetical strategy); treatment-policy = all randomised participants regardless of adherence (ITT). AE discontinuation = stopped study drug for any adverse event. Hover a status for its definition.
Verbatim quotes from the source (21)
- ecnoglutide 1.2 mg · weight_tp · Results, Secondary outcomes; Table 2
−4.74% (−5.65 to −3.82) with 1.2 mg ecnoglutide
- ecnoglutide 1.2 mg · ae_dc · Results, Safety outcomes; Table 3
TEAEs led to premature treatment discontinuation in 1 (1.4%) participant in each treatment group (Table 3).
- ecnoglutide 1.2 mg · disc_any · Results, Study participants (denominator 71 from Table 3/Fig
including 3 from the 0.6 mg ecnoglutide group, 4 from the 1.2 mg ecnoglutide group, and 2 from the pooled placebo group
- ecnoglutide 1.2 mg · nausea · Table 3
Nausea 9 (12.7) 5 (7.2) 7 (9.9)
- ecnoglutide 1.2 mg · sae · Results, Safety outcomes; Table 3
Serious TEAEs were reported in 2.9% (2/69) of the 0.6 mg ecnoglutide group, 4.2% (3/71) of the 1.2 mg ecnoglutide group, and 5.6% (4/71) of the placebo group.
- ecnoglutide 1.2 mg · hba1c · Results, Primary outcome; Table 2
−2.43% (−2.65 to −2.20) with 1.2 mg ecnoglutide
- ecnoglutide 1.2 mg · sbp · Results, Safety outcomes
a mean of 5.2 mmHg with 1.2 mg ecnoglutide
- 1.2 mg · weight_tp · press release
Percent weight reduction, % | -9.9 | -13.3 | -15.4 | -0.3
- 1.8 mg · weight_tp · press release
Percent weight reduction, % | -9.9 | -13.3 | -15.4 | -0.3
- 2.4 mg · weight_tp · press release
Percent weight reduction, % | -9.9 | -13.3 | -15.4 | -0.3
- 2.4 mg · weight_unsp · press release
the least-squares mean percentage change in body weight from baseline was -12.8% in the ecnoglutide group and -9.5% in the semaglutide group
- 0.6 mg · hba1c · press release
HbA1c change from baseline | -0.87 % | -1.96% ( P =0.0003) | -2.43% ( P< 0.0001)
- 0.6 mg · weight_unsp · press release
Percent body weight change from baseline | -2.02 % | -4.51% ( P =0.0002) | -4.74% ( P< 0.0001)
- 0.6 mg · ae_dc · press release
A total of three subjects, one (1.4%) from each cohort, discontinued the study due to adverse events.
- 0.6 mg · disc_any · Results, para 1
and safety set, and 9 (4%) of them discontinued treatment prematurely in the double-blind period, including 3 from the 0.6 mg ecnoglutide group, 4 from the 1.2 mg ecnoglutide group, and 2 from the pooled placebo group (r
- 0.6 mg · nausea · Table 3 (double-blind period, safety set; columns: 1.2 mg N=
Nausea 9 (12.7) 5 (7.2) 7 (9.9)
- 0.6 mg · sae · Table 3 (double-blind period, safety set; columns: 1.2 mg N=
Serious TEAEs 3 (4.2) 2 (2.9) 4 (5.6)
- 0.6 mg · hba1c · publication (abstract)
At week 32, mean HbA1c reductions were 1·91% (SE 0·05; -20·86 mmol/mol [0·53]) with ecnoglutide 0·6 mg
- 0.6 mg · ae_dc · publication
six (3%) of 206 patients in the ecnoglutide 0·6 mg group, eight (4%) of 208 patients in the ecnoglutide 1·2 mg group, and six (3%) of 207 patients in the dulaglutide group discontinued treatment due to adverse events
- 1.2 mg · hba1c · publication
1·89% (0·05; -20·69 mmol/mol [0·54]) with ecnoglutide 1·2 mg, and 1·65% (0·05; -18·02 mmol/mol [0·53]) with dulaglutide.
- 1.2 mg · ae_dc · publication
six (3%) of 206 patients in the ecnoglutide 0·6 mg group, eight (4%) of 208 patients in the ecnoglutide 1·2 mg group, and six (3%) of 207 patients in the dulaglutide group discontinued treatment due to adverse events
Registered trials (7)
From ClinicalTrials.gov and the atlas registry sweep; phase 3 and outcome trials first.
| Trial | Indication | Phase | Status | Start → primary completion | n | Result | Registry |
|---|---|---|---|---|---|---|---|
| SLIMMER-YOUNG A Study of Ecnoglutide Injection in Overweight or Obese Chinese Adolescents | Obesity | Phase 3 | not yet recruiting | 2026-10 → 2028-06 | 192 | not yet recruiting | NCT07836270 |
| KOA A Study of Econoglutide Injection in Obese Participants With Knee Osteoarthritis (KOA) | Knee OA | Phase 3 | recruiting | 2026-08 → 2028-05 | 360 | recruiting | NCT07734311 |
| NCT07434050 A Study of XW003 in Obese Participants With Obstructive Sleep Apnea Receiving Positive Airway Pressure Therapy | Sleep apnoea | Phase 3 | recruiting | 2026-03 → 2028-06 | 140 | recruiting | NCT07434050 |
| NCT07387094 A Study of XW003 in Obese Participants With Obstructive Sleep Apnea But Not Receive Positive Airway Pressure Therapy | Sleep apnoea | Phase 3 | recruiting | 2026-02 → 2027-12 | 140 | recruiting | NCT07387094 |
| SLIMMER A Phase 3 Study to Evaluate the Efficacy of XW003 in Adults With Overweight or Obesity | Obesity | Phase 3 | completed | 2023-04 → 2024-06 | 664 | Completed; arm-level results are in the atlas maps (Effect vs cost, Arms) | NCT05813795 |
| NCT05680129 A Phase 3 Study to Evaluate the Efficacy of XW003 Compared With Dulaglutide in Participants With T2DM | T2D | Phase 3 | completed | 2023-01 → 2024-07 | 623 | Completed; results not in the atlas yet | NCT05680129 |
| NCT05680155 A Phase 3 Study to Evaluate the Efficacy of XW003 Compared With Placebo in T2DM Patients | T2D | Phase 3 | completed | 2022-12 → 2024-06 | 211 | Completed; results not in the atlas yet | NCT05680155 |
Primary sources
- Zhu D, Wang W, Tong G, Ma J, Wen B, Zheng X, et al. Efficacy and safety of cAMP signalling-biased GLP-1 analogue ecnoglutide monotherapy versus placebo in patients with type 2 diabetes (EECOH-1): a multi-centre, randomised, double-blind, placebo-controlled, phase 3 trial. Nat Commun. 2026;17(1):1420. PMID: 41501026.
- Sciwind. Sciwind Biosciences Announces Publication of Phase III SLIMMER Trial Results in The Lancet Diabetes & Endocrinology (BioPharma Dive mirror of company release) [press release]. 2025-06-21. Available from: https://www.biopharmadive.com/press-release/20250621-sciwind-biosciences-announces-publication-of-phase-iii-slimmer-trial-result-1
- Sciwind. Head-to-head Study Validates the Clinical Advantage of New-generation Biased GLP-1: Ecnoglutide Delivers 35% Greater Weight Loss than Semaglutide (BioSpace mirror) [press release]. 2026-06-07. Available from: https://www.biospace.com/press-releases/head-to-head-study-validates-the-clinical-advantage-of-new-generation-biased-glp-1-ecnoglutide-delivers-35-greater-weight-loss-than-semaglutide
- Sciwind. Sciwind Biosciences Announces Positive Topline Results from Phase 3 Clinical Trial of Ecnoglutide (XW003) in Adult Patients with Type 2 Diabetes in China [press release]. 2024-01-02. Available from: https://www.prnewswire.com/news-releases/sciwind-biosciences-announces-positive-topline-results-from-phase-3-clinical-trial-of-ecnoglutide-xw003-a-long-acting-camp-signaling-biased-glp-1-analog-in-adult-patients-with-type-2-diabetes-in-china-302023591.html
- He Y, Mi N, Cheng Z, Xue H, Han J, Wang H, et al. Efficacy and safety of cAMP-biased GLP-1 receptor agonist ecnoglutide versus dulaglutide in patients with type 2 diabetes and elevated glucose concentrations on metformin monotherapy (EECOH-2): a 52-week, multicentre, open-label, non-inferiority, randomised, phase 3 trial. Lancet Diabetes Endocrinol. 2025;13(10):863-873. PMID: 40854315.
How to cite this page
Cite the primary publication for any single result; every value above links to it.